[Featured Stock] Seegene Surges 20% on News of New Product for Simultaneous Diagnosis of COVID-19, Cold, and Flu Viruses
[Asia Economy Reporter Oh Ju-yeon] Seegene's stock surged more than 20% during trading hours following the news that it launched a new product capable of simultaneously diagnosing COVID-19, cold, and flu viruses.
According to the Korea Exchange on the 8th, as of 11:23 AM, Seegene was trading at 294,000 KRW, up 20.25% compared to the previous trading day.
This is interpreted as a reaction to the announcement of a new 'twindemic' prevention product that can simultaneously differentiate and diagnose not only COVID-19 but also epidemic flu and cold viruses.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- Court Partially Grants Samsung Electronics' Injunction to Prohibit Industrial Action... 100 Million Won Penalty Per Day for Violations
- President Lee: "Corporate Management Rights Should Be Respected as Much as Labor Rights"...Final Samsung Labor-Management Negotiations (Comprehensive)
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Seegene announced that it will launch the diagnostic product 'AllplexTM SARS-CoV/FluA/FluB/RSV Assay,' which can test for various respiratory viruses including the COVID-19 virus at once, in the global market in September.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
